Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?
作者信息
Sasaki Koji, Kantarjian Hagop M, Jabbour Elias J
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
出版信息
Cancer. 2019 Nov 1;125(21):3891-3892. doi: 10.1002/cncr.32385. Epub 2019 Jul 10.
PMID:31291004
Abstract
摘要
相似文献
1
Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?对小剂量环磷酰胺联合伊奈妥单抗加或不加博纳吐单抗的回应：炒作还是希望？
Cancer. 2019 Nov 1;125(21):3891-3892. doi: 10.1002/cncr.32385. Epub 2019 Jul 10.
2
Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?小剂量高强度化疗联合伊奈妥单抗加或不加博纳吐单抗：是炒作还是希望？
Cancer. 2019 Nov 1;125(21):3890-3891. doi: 10.1002/cncr.32381. Epub 2019 Jul 10.
3
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.英妥珠单抗奥佐米星联合低强度化疗（mini-HCVD）与或不联合blinatumomab 对比标准强化化疗（HCVAD）作为费城染色体阴性急性淋巴细胞白血病老年患者一线治疗：倾向评分分析。
Cancer. 2019 Aug 1;125(15):2579-2586. doi: 10.1002/cncr.32139. Epub 2019 Apr 15.
4
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.在首次挽救性化疗中，采用奥加米星单抗联合 mini-hyper-CVD 的化疗免疫治疗，联合或不联合blinatumomab，对费城染色体阴性急性淋巴细胞白血病患者具有高度疗效。
Cancer. 2018 Oct 15;124(20):4044-4055. doi: 10.1002/cncr.31720. Epub 2018 Oct 11.
5
Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.致编辑的信的回复：关于奥英妥珠单抗与博纳吐单抗治疗复发或难治性急性淋巴细胞白血病的间接治疗比较
Adv Ther. 2020 Feb;37(2):958-962. doi: 10.1007/s12325-019-01169-0. Epub 2019 Dec 14.
6
Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147-2160. doi:10.1007/s12325-019-00991-w.致编辑的信：关于因诺妥珠单抗奥佐米星与博纳吐单抗治疗复发或难治性急性淋巴细胞白血病的间接治疗比较，普罗斯科罗夫斯基等人。《药物治疗进展》（2019年）；36(8):2147 - 2160。doi:10.1007/s12325 - 019 - 00991 - w。
Adv Ther. 2020 Feb;37(2):955-957. doi: 10.1007/s12325-019-01168-1. Epub 2019 Dec 14.
7
The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.成年B细胞急性淋巴细胞白血病患者免疫治疗基础要点
Ann Pharmacother. 2018 Mar;52(3):268-276. doi: 10.1177/1060028017736539. Epub 2017 Oct 12.
8
[Antibodies in hematology by the example of acute lymphatic leukemia].[以急性淋巴细胞白血病为例谈血液学中的抗体]
Internist (Berl). 2019 Oct;60(10):1032-1035. doi: 10.1007/s00108-019-00668-0.
9
Treatment of relapsed/refractory acute lymphoblastic leukemia.复发/难治性急性淋巴细胞白血病的治疗
Clin Adv Hematol Oncol. 2019 Mar;17(3):166-175.
10
Blinatumomab for Acute Lymphoblastic Leukemia.博纳吐单抗治疗急性淋巴细胞白血病
N Engl J Med. 2017 Jun 8;376(23):e49. doi: 10.1056/NEJMc1704012.
Zotero 插件